• Capsaicin: Applied Protocols and Innovations for TRPV1 Resea

  2026-05-02

  Capsaicin (E)-Capsaicin stands out as a unique research tool for TRPV1 ion channel activation and KDM1A/LSD1 inhibition, supporting advanced pain, itch, and gastric cancer models. This article delivers actionable protocol parameters, troubleshooting insights, and workflow enhancements, drawing on recent breakthroughs and practical expertise.

• Flavonoids and ABT-263 Overcome Radio-Resistant Senescence i

  2026-05-01

  Russo et al. (2022) developed and characterized novel radio-resistant osteosarcoma and colorectal cancer cell lines to model therapy-induced senescence. This work demonstrates that senolytic agents—including ABT-263 (Navitoclax) and natural flavonoids—synergistically enhance cell death after irradiation, suggesting new strategies for overcoming resistance in cancer therapy.

• Losmapimod (GW856553X): Applied Protocols for Inflammation R

  2026-04-30

  Losmapimod (GW856553X) offers researchers unprecedented dual-action p38 MAPK inhibition, enabling precise modulation of inflammatory signaling and vascular function. This guide translates recent structural and translational breakthroughs into actionable workflows, troubleshooting strategies, and advanced use-cases for APExBIO Losmapimod in cardiovascular and COPD models.

• CHIR-99021 (CT99021): Optimizing Wnt/β-Catenin Pathway Modul

  2026-04-30

  CHIR-99021 (CT99021) empowers researchers to reproducibly modulate the Wnt/β-catenin pathway, maintain embryonic stem cell pluripotency, and drive targeted differentiation. This guide delivers protocol-ready tips, advanced troubleshooting, and evidence-driven insights for maximizing results with APExBIO’s trusted GSK-3 inhibitor.

• Chloroquine in Autophagy and Pathway Research: Workflow Mast

  2026-04-29

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) stands out for its dual role as an autophagy inhibitor and pathway modulator in malaria, rheumatoid arthritis, and cancer research. This guide translates recent mechanistic breakthroughs and protocol innovations into actionable workflows, advanced troubleshooting, and competitive advantages for experimentalists.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Techn

  2026-04-29

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) minimizes endogenous protease-mediated protein degradation during extraction and sample preparation, especially when downstream applications are sensitive to divalent cations. It is not suitable where DMSO or the specific inhibitor panel may interfere with subsequent steps or for long-term storage of working solutions.

• Verteporfin in Photodynamic Therapy: Applied Workflows & Inn

  2026-04-28

  Verteporfin enables precise, dual-action research in photodynamic therapy and autophagy modulation, expanding its utility beyond ocular neovascularization. Leveraging mechanistic insights and workflow optimizations, this guide empowers researchers to achieve high reproducibility and troubleshoot common challenges in advanced cell-based assays.

• CHIR 99021 Trihydrochloride: Precision GSK-3 Inhibition in H

  2026-04-28

  Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor, enables precise modulation of self-renewal and differentiation in human intestinal organoids. Discover unique assay strategies and reference-backed protocols for advanced stem cell and metabolic research.

• QPRT Drives Breast Cancer Invasiveness via Rho/ROCK-Myosin P

  2026-04-27

  Liu et al. (2021) demonstrate that quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by promoting myosin light chain phosphorylation through the Rho/ROCK signaling cascade. Their mechanistic findings suggest QPRT as a potential prognostic marker and therapeutic target in aggressive breast cancer.

• Canagliflozin Remodels Mitochondria in Diabetic Mouse Kidney

  2026-04-27

  This study reveals that canagliflozin, a selective SGLT2 inhibitor, not only lowers glucose but also remodels mitochondrial structure and improves bioenergetic function in proximal tubular cells of hypertensive–diabetic mice. These findings provide mechanistic insight into renal protective effects, expanding the therapeutic relevance of SGLT2 inhibitors in kidney disease research.

• Protease Inhibitor Cocktail EDTA-Free (100X in DMSO): Techni

  2026-04-26

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) addresses proteolytic degradation during protein extraction and sample preparation, particularly where preservation of divalent cations is necessary. It is suitable for workflows such as Western blotting, co-immunoprecipitation, and phosphorylation analysis. This product should not be used when EDTA-mediated metalloprotease inhibition is required.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Techn

  2026-04-25

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents protein degradation during extraction and sample prep, especially in workflows sensitive to divalent cations. It is not suitable for protocols requiring metalloprotease inhibition by chelation. For optimal results, integrate this cocktail into workflows such as Western blotting, co-immunoprecipitation, and kinase assays.

• LGK-974: Precision PORCN Inhibitor for Wnt Pathway Research

  2026-04-24

  LGK-974 empowers researchers to dissect and modulate Wnt signaling with nanomolar precision, offering robust tumor suppression in Wnt-dependent models while maintaining high cell viability. This article details actionable workflows, troubleshooting strategies, and direct assay enhancements that set LGK-974 apart as a benchmark PORCN inhibitor for translational oncology and developmental biology.

• Neuroinflammation and Piezo2 Signaling in Trigeminal Allodyn

  2026-04-24

  Liao et al. uncover how neuroinflammatory responses from trigeminal nerve root compression drive mechanical allodynia through a Ca2+-dependent CGRP/SP-Piezo2 axis. Their integrative in vivo and in vitro analyses delineate a feedback loop between neuropeptide signaling and mechanotransduction, providing a new mechanistic framework for trigeminal neuralgia pathogenesis.

• Brefeldin A: Translational Leverage in ER Stress and Cancer

  2026-04-23

  This thought-leadership article explores the mechanistic depth and translational potential of Brefeldin A (BFA) as a vesicle transport inhibitor, ER stress inducer, and apoptosis modulator in cancer and endothelial injury models. Integrating recent evidence and protocol intelligence, it provides actionable guidance for researchers seeking robust, reproducible results. By bridging bench insights with strategic vision, this piece uniquely positions BFA from APExBIO as more than a reagent—it's a catalyst for discovery.

15969 records 1/1065 page Next 12345 下5页 Last page